Tegafur/gimeracil/oteracil poatssium複方製劑(如TS-1）
(103/6/1)：
治療局部晚期無法手術切除或轉移性胰臟癌病人。
2013年12月20日 星期五
2013年腸胃道癌症重大進展回顧 (美國臨床腫瘤醫學會ASCO)
1. Octreotide LAR prolongs overall survival in some patients with a rare form of GI cancer.
Octreotide LAR (長效型Octreotide) 可延長某些神經內分泌瘤癌症病患的整體存活時間
2. Maintenance treatment with capecitabine and bevacizumab extends overall survival in patients with inoperable metastatic colorectal cancer.
以Capecitabine與bevacizumab維持性化療可延長轉移性大腸直腸癌病患的整體存活
3. Patients with colorectal cancer harboring NRAS mutations are unlikely to benefit from panitumumab.
有NRAS或KRAS基因突變之大腸直腸癌病患, 使用EGFR單株抗體 panitumumab, 無顯著的療效
4. Large phase III study establishes a new standard treatment option for patients with metastatic pancreatic cancer.
大型臨床試驗顯示, 使用nab-paclitaxel ( 奈米微粒劑型紫杉醇) 與gemcitabine(健澤) 可增加病患的整體存活以及延長疾病惡化時間
5. Postoperative treatment with S-1 chemotherapy reduces relapses and extends survival in Asian patients with pancreatic cancer.
亞洲人的胰臟病患, 術後使用S1輔助性化學治療, 可降低復發機率, 以及增加整體存活時間
參考資料
- Arnold R, Wittenberg M, Rinke A, et al: Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival. J Clin Oncol 31, 2013 (suppl; abstr 4030)
- Koopman M, Simkens LHJ, Ten Tije AJ, et al: Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 31, 2013 (suppl; abstr 3502)
- Douillard J-Y, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1334, 2013
- Von Hoff DD, Ervin TJ, Arena FP, et al: Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol 31, 2013 (suppl; abstr 4005^)
- US Food and Drug Administration: FDA approves Abraxane for late-stage pancreatic cancer.
- Fukutomi A, Uesaka K, Boku N, et al: JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer.J Clin Oncol 31, 2013 (suppl; abstr 4008)
2013年5月27日 星期一
Gemcitabine（如Gemzar）健澤 (健保給付規定2010/10/1): 非小細胞肺癌, 胰臟癌, 乳癌, 膀胱癌, 卵巢癌
Gemcitabine（如Gemzar）：（92/12/1、93/8/1、94/10/1、96/5/1、99/10/1）
限用於
1.晚期或無法手術切除之非小細胞肺癌及胰臟癌病患。
2.晚期膀胱癌病患。（92/12/1）
3.Gemcitabine與paclitaxel併用，可使用於曾經使用過anthracycline之局部復發且無法手術切除或轉移性之乳癌病患。（94/10/1）
4.用於曾經使用含鉑類藥物 (platinum-based) 治療後復發且間隔至少6個月之卵巢癌，作為第二線治療。（96/5/1、99/10/1）
訂閱：
意見 (Atom)